MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by GURTOO, H. L.
Right arrow Articles by CAMPBELL, T. C.
Right arrow Search for Related Content
PubMed
Right arrow Articles by GURTOO, H. L.
Right arrow Articles by CAMPBELL, T. C.

Molecular Pharmacology, Vol 10, 776-789, Copyright © 1974 by the American Society for Pharmacology and Experimental Therapeutics

Metabolism of Aflatoxin B1 and Its Metabolism-Dependent and Independent Binding to Rat Hepatic Microsomes

HIRA L. GURTOO 1 and T. COLIN CAMPBELL 1

1 Department of Experimental Therapeutics and J. T. Grace, Jr., Cancer Drug Center, Roswell Park Memorial Institute, Buffalo, New York 14203, and Department of Biochemistry and Nutrition, Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061

The NADPH-mediated metabolism of aflatoxin B1 by rat hepatic microsomes was studied by means of difference spectroscopy. A decrease in absorbance at 360 nm, due to the disappearance of aflatoxin B1 during its metabolism, was caused by the formation of a metabolite having a spectral peak at 398 nm. From the solubility, spectral, and microsomal binding characteristics, this metabolite appears to be aflatoxin B2a (aflatoxin hemiacetal). Difference spectroscopic studies on microsomes reisolated from incubation mixtures containing aflatoxin B1 with or without NADPH showed that aflatoxin B1 was bound to microsomes, giving a complex having a spectral peak at 360 nm; this binding did not require NADPH and the complex could be separated by gel filtration chromatography. A metabolite of aflatoxin B1, the formation of which was NADPH-dependent, was bound to microsomes, yielding a complex having a spectral peak at 405 nm; this complex was not dissociated by gel chromatography on by treatment with trichloracetic acid or extraction with chloroform and acetone. SKF 525-A and L-cysteine inhibited the formation of this complex, the former by inhibiting the metabolic conversion of aflatoxin B1 to aflatoxin B2a and the latter by blocking the binding of the metabolite to microsomes. Aflatoxin B1 and aflatoxin B2a appeared to bind to different sites on the microsomes. A change in pH caused an alteration in the structure of aflatoxin B2a and its extraction with chloroform. pH equilibria for this phenomenon were estimated to be 3.00 and 7.35. Based on these studies, it is proposed that aflatoxin B2a, under alkaline conditions, cleaves to yield a dialdehyde derivative(s) which binds to microsomes, forming Schiff bases with free amino groups. These studies also indicate that, under certain conditions, rat hepatic microsome-mediated conversion of aflatoxin B1 to a water-soluble metabolite, which appears to be aflatoxin B2a, represents a major metabolic pathway.

Note:
ACKNOWLEDGMENTS We gratefully acknowledge the valuable criticism provided by Drs. H. Schwartz, C. Dave, and F. Rosen during the preparation of this manuscript, and are also thankful to Miss L. Caballes for her assistance in radiochemical experiments and to Mr. L. Motycka for his skilled technical assistance. We also wish to express our deep appreciation and thanks to Dr. E. Mihich for his continued encouragement and interest in this work.

Submitted on March 12, 1974







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1974 by the American Society for Pharmacology and Experimental Therapeutics